Original study of TMED3 on tumor came from prostate cancer by Vainio et al. [10] reporting that TMED3 whose mRNA was shown to be highly expressed in prostate cancer and high mRNA of TMED3 significantly correlated with AR and ERG oncogene expression, indicating the oncogenic trait of TMED3 that could be used as potential drug target in prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.